Literature DB >> 24482710

Monitoring of peri-distal gastrectomy carbohydrate antigen 19-9 level in gastric juice and its significance.

A-Man Xu1, Lei Huang1, Wen-Xiu Han1, Zhi-Jian Wei1.   

Abstract

Gastric carcinoma is one of the most common and deadly malignancies nowadays, and carbohydrate antigen 19-9 (CA 19-9) in gastric juice has been rarely studied. To compare peri-distal gastrectomy (DG) gastric juice and serum CA 19-9 and reveal its significance, we selected 67 patients diagnosed with gastric carcinoma who underwent DG, and collected their perioperative gastric juice whose CA 19-9 was detected, with serum CA 19-9 monitored as a comparison. We found that: gastric juice CA 19-9 pre-gastrectomy was significantly correlated with tumor TNM classification, regarding tumor size, level of gastric wall invaded, differentiated grade and number of metastatic lymph nodes as influencing factors, while serum CA 19-9 revealed little information; gastric juice CA 19-9 was significantly correlated with radical degree, and regarded number of resected lymph nodes and classification of cutting edge as impact factors; thirteen patients whose gastric juice CA 19-9 rose post-DG showed features indicating poor prognosis; the difference of gastric juice CA 19-9 between pre- and post-gastrectomy was correlated with tumor TNM classification and radical degree, and regarded tumor size, number of resected metastatic and normal lymph nodes, sum of distances from tumor to cutting edges and classification of cutting edge as influential factors. We conclude that peri-DG gastric juice CA 19-9 reveals much information about tumor and radical gastrectomy, and may indicate prognosis; while serum CA 19-9 has limited significance.

Entities:  

Keywords:  Gastric carcinoma; carbohydrate antigen 19-9; distal gastrectomy; gastric juice; perioperative

Year:  2014        PMID: 24482710      PMCID: PMC3902262     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  38 in total

1.  Levels of CEA and Ca 19 - 9 in the sera and peritoneal cavity in patients with gastric and pancreatic cancers.

Authors:  David Hoskovec; Jozef Varga; Ellen Konečná; Frantisek Antos
Journal:  Acta Cir Bras       Date:  2012-06       Impact factor: 1.388

2.  Study of serum antioxidant capacity and relation with CA 19-9 and PSA in patients with gastrointestinal tract and prostate tumors.

Authors:  M López Vélez; F Martínez Martínez
Journal:  Clin Biochem       Date:  2011-06-24       Impact factor: 3.281

3.  The prognosis of gastric cancer patients with marginally elevated carcinoembryonic antigen (CEA) values after D2 radical gastrectomy.

Authors:  Shi Chen; Xing-Yu Feng; Yuan-Fang Li; Bai-Wei Zhao; Zhi-Wei Zhou; Ying-Bo Chen
Journal:  J Surg Oncol       Date:  2013-01-07       Impact factor: 3.454

4.  The pattern of lymph node metastasis and the suitability of 7th UICC N stage in predicting prognosis of remnant gastric cancer.

Authors:  Fangxuan Li; Rupeng Zhang; Han Liang; Hui Liu; Jichuan Quan; Jingzhu Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-03       Impact factor: 4.553

5.  Immunohistochemical studies on the main entrance-route of CA19-9 into the peripheral venous blood of gastric cancer patients. Correlation with CA19-9 levels in peripheral and portal blood.

Authors:  Y Tabuchi; H Deguchi; K Imanishi; Y Saitoh
Journal:  Cancer       Date:  1990-10-01       Impact factor: 6.860

6.  Gastric micropapillary carcinoma: A distinct subtype with a significantly worse prognosis in TNM stages I and II.

Authors:  Dae-Woon Eom; Gil Hyun Kang; Sang Hak Han; Gab Jin Cheon; Koon Hee Han; Ho-Suk Oh; Ji-Hun Kim; Hyuk-Jai Jang; Seung-Mo Hong
Journal:  Am J Surg Pathol       Date:  2011-01       Impact factor: 6.394

7.  Gastric cancer.

Authors:  Henk H Hartgrink; Edwin P M Jansen; Nicole C T van Grieken; Cornelis J H van de Velde
Journal:  Lancet       Date:  2009-07-20       Impact factor: 79.321

8.  CA 19-9 determination in gastric juice: role in identifying gastric cancer and high risk patients.

Authors:  F Farinati; D Nitti; F Cardin; F Di Mario; F Costa; C Rossi; A Marchett; M Lise; R Naccarato
Journal:  Eur J Cancer Clin Oncol       Date:  1988-05

9.  Gastric juice miR-129 as a potential biomarker for screening gastric cancer.

Authors:  Xing Yu; Lin Luo; Yibo Wu; Xiuchong Yu; Yang Liu; Xuelin Yu; Xiaoyan Zhao; Xinjun Zhang; Long Cui; Guoliang Ye; Yanping Le; Junming Guo
Journal:  Med Oncol       Date:  2013-01-10       Impact factor: 3.064

10.  Comparison between clinical significance of serum proinflammatory proteins (IL-6 and CRP) and classic tumor markers (CEA and CA 19-9) in gastric cancer.

Authors:  Marta Lukaszewicz-Zając; Barbara Mroczko; Mariusz Gryko; Bogusław Kędra; Maciej Szmitkowski
Journal:  Clin Exp Med       Date:  2010-10-12       Impact factor: 3.984

View more
  6 in total

Review 1.  Detection of digestive malignancies and post-gastrectomy complications via gastrointestinal fluid examination.

Authors:  Lei Huang; Aman Xu
Journal:  Front Med       Date:  2017-03-02       Impact factor: 4.592

2.  CD147 and MMP-9 expressions in type II/III adenocarcinoma of esophagogastric junction and their clinicopathological significances.

Authors:  Lei Huang; A-Man Xu; Qiang Peng
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

Review 3.  Epithelial-mesenchymal transition in gastric cancer.

Authors:  Lei Huang; Ruo-Lin Wu; A-Man Xu
Journal:  Am J Transl Res       Date:  2015-11-15       Impact factor: 4.060

4.  Transglutaminase 2 in cancer.

Authors:  Lei Huang; A-Man Xu; Wei Liu
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

5.  Inhibitory effects of isocryptotanshinone on gastric cancer.

Authors:  Zhang-Ming Chen; Lei Huang; Miao-Miao Li; Lei Meng; Song-Cheng Ying; A-Man Xu
Journal:  Sci Rep       Date:  2018-06-18       Impact factor: 4.379

6.  LDH-Apromotes epithelial-mesenchymal transition by upregulating ZEB2 in intestinal-type gastric cancer.

Authors:  Yongjie Zhang; Sen Lin; Yan Chen; Fei Yang; Shenlin Liu
Journal:  Onco Targets Ther       Date:  2018-04-27       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.